CDP-Choline for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

CDP-Choline for Health & Longevity

Created on 06/20/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

CDP-Choline is a naturally occurring molecule taken as a supplement to supply the brain with building blocks for cell membranes and a key memory-related signaling chemical. It carries an unusually clean safety record. The cognitive upside is plausible but not firmly proven, appearing greatest in those already experiencing memory slowing — real promise paired with real uncertainty. (Full Review)

Protocol

Standard Dose
500 mg/day
Often the branded Cognizin form, taken for at least 12 weeks
Timing
Morning or midday, with food
Earlier dosing avoids sleep disruption; food reduces nausea
Titration
Start ~250 mg/day
Increase toward 500 mg/day over 1–2 weeks if tolerated
Time to effect
Memory
~12 weeks
Healthy-older-adult memory study measured outcomes at 12 weeks
Attention
~4 weeks
Attention and psychomotor speed improved over 28 days
Onset
Weeks, not days
No acute same-day effects; expect a multi-week trial period

Benefits

Contraindications
  • Pregnancy or breastfeeding (untested)
  • Established cardiovascular disease (theoretical TMAO concern)
    •
Key Interactions
  • Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)
  • Levodopa
  • Other choline donors (alpha-GPC, choline bitartrate)
  • Stimulants such as caffeine
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Gastrointestinal upset; headache and insomnia
    •
  • Speculative: Excitability or agitation; theoretical cardiovascular concern via TMAO; unknown long-term safety
    •

Monitoring

Marker Target Why
TMAO (trimethylamine-N-oxide) Lower is generally better; no consensus cutoff Screens the theoretical choline-to-cardiovascular pathway
Homocysteine < 7–8 µmol/L Reflects choline/methylation status, relevant to brain aging
hs-CRP < 1.0 mg/L Inflammation marker relevant to brain and vascular aging
Fasting lipid panel Tighter than standard reference ranges Cardiovascular context given the theoretical TMAO concern

Cadence: Reassess cognitive measures at baseline, ~6 and 12 weeks, then every 3–6 months; optional bloodwork every 6–12 months if tracking cardiovascular context.

Qualitative Assessment

  • Subjective memory and recall in daily life
  • Focus, attention, and mental clarity during demanding tasks
  • Mental fatigue and energy across the day
  • Sleep quality (to detect any dosing-related disruption)
  • Mood and overall sense of cognitive wellbeing
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.